Abstract
Eye is a vital sense organ of our body and any disorder can lead to serious medical implications that may put great financial burden on patient and their family. Effective drug delivery to the eye is a challenging proposition for the pharmaceutical scientist. Eye drops have been globally accepted as a formulation for anterior segment applications. On one hand it is widely used owing to its convenience but is also associated with some limitations in terms of desired pharmacological and pharmacokinetic profile, dosing frequency, systemic untoward effects, patient noncompliance, low drug bioavailability due to transient contact time, rapid washout by tearing and nasolacrimal drainage. The need to overcome these major issues related to ocular pharmacotherapy has been long recognized. Several novel nanocarriers including nanolipid based carrier systems have been widely explored and investigated for ophthalmic applications. These include solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes, in situ gels, niosomes, mucoadhesive systems and discomes. Since lipids have similar structure to human cell lipids, their biodegradable, non-toxic and biocompatible profile are particularly useful. Additionally, they also offer protection against drug degradation, impart controlled drug release characteristics and site specific delivery. This review explores the potential feasibility of lipid component in formulation of nanomedicine for ophthalmic delivery and reports the clinical findings in order to improve the ocular pharmacotherapy. Here, we also discussed for patents related to the topic.
Keywords: Biodegradation, eye, lipid nanocarrier, ophthalmic delivery, patents.
Graphical Abstract
Recent Patents on Nanotechnology
Title:Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers
Volume: 9 Issue: 2
Author(s): Abhishek K. Sah and Preeti K. Suresh
Affiliation:
Keywords: Biodegradation, eye, lipid nanocarrier, ophthalmic delivery, patents.
Abstract: Eye is a vital sense organ of our body and any disorder can lead to serious medical implications that may put great financial burden on patient and their family. Effective drug delivery to the eye is a challenging proposition for the pharmaceutical scientist. Eye drops have been globally accepted as a formulation for anterior segment applications. On one hand it is widely used owing to its convenience but is also associated with some limitations in terms of desired pharmacological and pharmacokinetic profile, dosing frequency, systemic untoward effects, patient noncompliance, low drug bioavailability due to transient contact time, rapid washout by tearing and nasolacrimal drainage. The need to overcome these major issues related to ocular pharmacotherapy has been long recognized. Several novel nanocarriers including nanolipid based carrier systems have been widely explored and investigated for ophthalmic applications. These include solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes, in situ gels, niosomes, mucoadhesive systems and discomes. Since lipids have similar structure to human cell lipids, their biodegradable, non-toxic and biocompatible profile are particularly useful. Additionally, they also offer protection against drug degradation, impart controlled drug release characteristics and site specific delivery. This review explores the potential feasibility of lipid component in formulation of nanomedicine for ophthalmic delivery and reports the clinical findings in order to improve the ocular pharmacotherapy. Here, we also discussed for patents related to the topic.
Export Options
About this article
Cite this article as:
K. Sah Abhishek and K. Suresh Preeti, Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers, Recent Patents on Nanotechnology 2015; 9 (2) . https://dx.doi.org/10.2174/187221050902150819151841
DOI https://dx.doi.org/10.2174/187221050902150819151841 |
Print ISSN 1872-2105 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4020 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nucleic Acids Electro-transfer: From Bench to Bedside
Current Drug Metabolism TGFb and its Smad Connection to Cancer
Current Genomics Plant PARPs, PARGs and PARP-like Proteins
Current Protein & Peptide Science Signal Transducers and Activators of Transcription (STATs): Novel Targets of Chemopreventive and Chemotherapeutic Drugs
Current Cancer Drug Targets Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors
Current Chemical Biology How to Generate Reliable and Predictive CoMFA Models
Current Medicinal Chemistry Pharmacokinetics of Selegiline in a Rabbit Model
Letters in Drug Design & Discovery FBXW7alpha Promotes the Recovery of Traumatic Spinal Cord
Current Molecular Medicine Targeting Complement in Rheumatoid Arthritis
Current Rheumatology Reviews Ulcerative Colitis: Pathogenesis
Current Drug Targets Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Relationship Between Epithelial Barrier and Microorganisms (Guest Editor: Nadia Berkova)]
Current Immunology Reviews (Discontinued) Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Structural Analysis of Relevant Drug Targets for Alzheimer's Disease: Novel Approaches to Drug Development
Current Bioactive Compounds <i>Plasmodium falciparum</i> Heat Shock Protein 70 Lacks Immune Modulatory Activity
Protein & Peptide Letters Ginsenosides from the Leaves and Flower Buds of Panax ginseng and their Pharmacological Effects
Current Bioactive Compounds Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design Nitric Oxide Related Therapeutic Phenomenon: A Challenging Task
Current Pharmaceutical Design